Drug
Sarilumab clinical trials
Also written REGN88, Kevzara® and SAR153191.
- studies test it
- 47
- open now
- 9
- in phase 3
- 16
- first study started
- 2007
Keep track of what changes. Save the sarilumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
47 studies that test it; most in 2020 (10)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 7 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 10 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 12
- Phase 2
- 24
- Phase 3
- 16
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 21
Sanofi (21) · Regeneron Pharmaceuticals (5) · M.D. Anderson Cancer Center (1) · Wei-Che Ko (1) · Assistance Publique - Hôpitaux de Paris (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Stanford University (1) · Maimónides Biomedical Research Institute of Córdoba (1)
Often tested with
Tested in the same studies.
Adalimumab (3) · Tocilizumab (3) · Cemiplimab (2) · Baricitinib (2) · Hydroxychloroquine (2) · Dupilumab (1) · Ustekinumab (1) · Guselkumab (1)
Studies
Open first, then newest update. How each study uses sarilumab is read from its arms, and is right about nine times in ten.
Testing it · 47
- Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticaRecruitingPhase 3SanofiNCT07286214Written as Sarilumab
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)RecruitingPhase 2SanofiNCT02991469Written as Sarilumab SAR153191 (REGN88)
- Phase 1b/2 Study of IV Sarilumab in Adult With RARecruitingPhase 1/2SanofiNCT07704580Written as Sarilumab, SAR153191 SC
- Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse EventsNot yet recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07836101Written as Sarilumab
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as Sarilumab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Sarilumab + Cemiplimab + Paclitaxel
- A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)RecruitingPhase 1/2University of Southern CaliforniaNCT04333706Written as Sarilumab 150mg or 200 mg plus Capecitabine
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingPhase 2NYU Langone HealthNCT05428007Written as Sarilumab
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Sarilumab
- A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.Active, not recruitingPhase 1M.D. Anderson Cancer CenterNCT05704634Written as Kevzara (Sarilumab)
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingPhase 2/3Wei-Che KoNCT05535738Written as Sarilumab
- Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19WithdrawnPhase 2BayCare Health SystemNCT07196306Written as Sarilumab 200 MG/1.14 ML Subcutaneous Solution
- Sarilumab COVID-19CompletedPhase 3SanofiNCT04327388Written as Sarilumab SAR153191
- Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARICompletedPhase 2/3Assistance Publique - Hôpitaux de ParisNCT04324073Written as Sarilumab
- Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic MastocytosisCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03770273Written as sarilumab
- An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)CompletedPhase 2SanofiNCT02776735Written as Sarilumab
- Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male SubjectsCompletedPhase 1SanofiNCT06159452Written as SAR153191-P3 drug product
- Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisCompletedPhase 2Stanford UniversityNCT04008069Written as Sarilumab
- Study on the Use of Sarilumab in Patients With COVID-19 InfectionWithdrawnEarly Phase 1ASST Fatebenefratelli SaccoNCT04386239Written as Sarilumab Prefilled Syringe
- Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid ArthritisTerminatedPhase 1/2University of Southern DenmarkNCT04842981Written as Sarilumab
See all 47 studies that test sarilumab →
Given in every arm · 12 — sarilumab is usual care beside what is tested
- A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Regeneron PharmaceuticalsNCT07154290Written as Sarilumab
- REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsNot yet recruitingPhase 1/2Regeneron PharmaceuticalsNCT07850921Written as Sarilumab Prophylaxis (Contingency)
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03564340Written as Sarilumab
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingPhase 1/2Regeneron PharmaceuticalsNCT04590326Written as Sarilumab
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as Sarilumab
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHDNot yet recruitingPhase 1Stanford UniversityNCT07484113Written as Sarilumab
- Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIROSuspendedPhase 2/3Assistance Publique - Hôpitaux de ParisNCT04341870Written as Sarilumab
- A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)CompletedPhase 3SanofiNCT02373202Written as Sarilumab
- A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)CompletedPhase 3SanofiNCT02293902Written as Sarilumab SAR153191 (REGN88)
- To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisCompletedPhase 3SanofiNCT02057250Written as Sarilumab
- Sarilumab Effect on the Pharmacokinetics of SimvastatinCompletedPhase 1SanofiNCT02017639Written as sarilumab SAR153191 (REGN88)
- Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid ArthritisCompletedPhase 1SanofiNCT01850680Written as sarilumab SAR153191 (REGN88)
As the comparator · 1 — what is tested is compared with sarilumab
Codes
What other systems call sarilumab · ClinicalTrials.gg INT000092
- MeSH (NLM) C000592401sarilumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) NU90V55F8ISARILUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1923319Confirmed FDA, Wikidata
- Wikidata Q7424081sarilumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152302SarilumabOne source FDA
- DrugBank DB11767One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592401 | sarilumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | NU90V55F8I | SARILUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1923319 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7424081 | sarilumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152302 | Sarilumab | One source FDA |
| DrugBank | DB11767 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.